Swiss drugmaker Novartis said on Friday it had agreed to buy all remaining rights to Ofatumumab from Britain’s GlaxoSmithKline.
Swiss drugmaker Novartis said on Friday it had agreed to buy all remaining rights to Ofatumumab from Britain’s GlaxoSmithKline.